Cell:转录因子FoxP3的突变减缓关节炎加剧糖尿病

2012-05-19 liuchun 生物谷

在多数免疫和炎症环境下,淋巴内稳态是由各种各样的调节性T细胞和转录因子FoxP3与特异的转录辅因子的相互作用来共同维持。 5月10日,Cell在线发表了哈佛医学院和凯特林癌症中心合作的一篇题为《An N-Terminal Mutation of the F oxp3 Transcription Factor Alleviates Arthritis but Exacerbates Diabete

在多数免疫和炎症环境下,淋巴内稳态是由各种各样的调节性T细胞和转录因子FoxP3与特异的转录辅因子的相互作用来共同维持。

5月10日,Cell在线发表了哈佛医学院和凯特林癌症中心合作的一篇题为《An N-Terminal Mutation of the F oxp3 Transcription Factor Alleviates Arthritis but Exacerbates Diabetes》研究文章,发现转录因子FoxP3 N末端的一个突变可以减缓关节炎,反而却加剧糖尿病。

研究报道了FoxP3的一个普通插入突变(GFP-Foxp3)改变了分子相互作用:阻止了与HIF- 1a却提高了与IRF4的相互作用。这些调节性T细胞的侧面发生轻微地改变,导致过分地呈现依赖IRF4的转录子活性。GFP- FoxP3小鼠在保持调节性T细胞依赖IRF4的功能优先地抑制T细胞帮助B细胞、Th2和Th17等细胞类型的分化的同时,却对自身免疫病表现出相异的敏感性:在K/BxN模型中对抗体介导的关节炎起防护作用,而在NOD背景的小鼠中对糖尿病表现出更高的易感性。

FoxP3分子的相互作用可以影响调节性T细胞的特异子功能和它们调节的免疫疾病,最终导致相异的免疫调节。

doi.org/10.1016/j.immuni.2012.04.007

PMC:
PMID:

An N-Terminal Mutation of the Foxp3 Transcription Factor Alleviates Arthritis but Exacerbates Diabetes

Jaime Darce1,Dipayan Rudra2,Li Li1,Junko Nishio1,Daniela Cipolletta1,Alexander Y. Rudensky2,Diane Mathis1,Christophe Benoist1

1 Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA

2 Howard Hughes Medical Institute and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

Received 19 July 2011. Revised 12 January 2012. Accepted 4 April 2012. Available online 10 May 2012. Published online: May 10, 2012.

Summary

Maintenance of lymphoid homeostasis in a number of immunological and inflammatory contexts is served by a variety of regulatory T (Treg) cell subtypes and depends on interaction of the transcription factor FoxP3 with specific transcriptional cofactors. We report that a commonly used insertional mutant of FoxP3 (GFP-Foxp3) modified its molecular interactions, blocking HIF-1α but increasing IRF4 interactions. The transcriptional profile of these Treg cells was subtly altered, with an overrepresentation of IRF4-dependent transcripts. In keeping with IRF4-dependent function of Treg cells to preferentially suppress T cell help to B cells and Th2 and Th17 cell-type differentiation, GFP-FoxP3 mice showed a divergent susceptibility to autoimmune disease: protection against antibody-mediated arthritis in the K/BxN model, but greater susceptibility to diabetes on the NOD background. Thus, specific subfunctions of Treg cells and the immune diseases they regulate can be influenced by FoxP3's molecular interactions, which result in divergent immunoregulation.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747159, encodeId=39ea1e47159af, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 03 14:15:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958737, encodeId=fe691958e3739, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 16 01:15:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653779, encodeId=f3dc1653e79cb, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Jun 11 00:15:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868506, encodeId=cae01868506bb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 22 11:15:00 CST 2012, time=2012-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265093, encodeId=d1dd126509318, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537438, encodeId=6d25153e43895, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2012-06-03 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747159, encodeId=39ea1e47159af, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 03 14:15:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958737, encodeId=fe691958e3739, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 16 01:15:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653779, encodeId=f3dc1653e79cb, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Jun 11 00:15:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868506, encodeId=cae01868506bb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 22 11:15:00 CST 2012, time=2012-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265093, encodeId=d1dd126509318, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537438, encodeId=6d25153e43895, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2013-03-16 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747159, encodeId=39ea1e47159af, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 03 14:15:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958737, encodeId=fe691958e3739, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 16 01:15:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653779, encodeId=f3dc1653e79cb, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Jun 11 00:15:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868506, encodeId=cae01868506bb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 22 11:15:00 CST 2012, time=2012-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265093, encodeId=d1dd126509318, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537438, encodeId=6d25153e43895, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2012-06-11 zhs3890
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747159, encodeId=39ea1e47159af, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 03 14:15:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958737, encodeId=fe691958e3739, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 16 01:15:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653779, encodeId=f3dc1653e79cb, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Jun 11 00:15:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868506, encodeId=cae01868506bb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 22 11:15:00 CST 2012, time=2012-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265093, encodeId=d1dd126509318, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537438, encodeId=6d25153e43895, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747159, encodeId=39ea1e47159af, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 03 14:15:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958737, encodeId=fe691958e3739, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 16 01:15:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653779, encodeId=f3dc1653e79cb, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Jun 11 00:15:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868506, encodeId=cae01868506bb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 22 11:15:00 CST 2012, time=2012-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265093, encodeId=d1dd126509318, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537438, encodeId=6d25153e43895, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1747159, encodeId=39ea1e47159af, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 03 14:15:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958737, encodeId=fe691958e3739, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 16 01:15:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653779, encodeId=f3dc1653e79cb, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Jun 11 00:15:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868506, encodeId=cae01868506bb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 22 11:15:00 CST 2012, time=2012-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265093, encodeId=d1dd126509318, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537438, encodeId=6d25153e43895, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]

相关资讯

Anesthesiology:针刺预处理具有强大免疫调节作用

近日,国际著名杂志Anesthesiology刊登了来自上海交通大学医学院附属仁济医院的研究人员的研究成果“Electroacupuncture Improves Survival in Rats with Lethal Endotoxemia via the Autonomic Nervous System,”,文章中,研究者发现针刺预处理具有强大的免疫调节作用,可使内毒素血症大鼠的生存率由20

PLoS One:研究证实蜜蜂可对抗真菌 自我医疗

美国北卡罗莱纳州立大学的一项研究显示,当蜂群感染上有害的真菌时,蜜蜂会“自我治疗”,采集更多数量的抗真菌植物树脂,以抵挡真菌的侵袭。 相关论文3月29日在线发表于《公共科学图书馆.综合》(PLoS ONE),论文的主要作者北卡州立大学昆虫系的博士后研究员迈克尔 西蒙妮-芬斯特隆(Michael Simone-Finstrom)说,让工蜂耗费精力采集这些树脂,演化出这种行为应该是由于其利大于弊。

Nature:美科学家发现PPAR-γ 的重要作用

5月16日,Nature在线发表了哈佛医学院微生物与免疫学系等机构的一篇题为PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells 的研究论文,揭示了噻唑烷二酮药物作用疾病的细胞机制,并证明了具有独特功能的调节性T细胞的独立类群能精确地用于治疗疾病。 在过去的几十年来,肥胖和Ⅱ

J. Med. Chem.:新型肽有助于治疗多种炎症性疾病

据物理学家组织网5月14日报道,一个国际研究小组基于自然产生的C3a肽,研制出了一种候选药物。C3a肽是调节免疫反应的核心成员,能够增强或阻止其活动影响的药物或将有助于治疗哮喘、类风湿性关节炎和败血症等多种炎症性疾病。相关研究报告发表在近期出版的《药物化学杂志》上。 研究团队首先创建了名为C3a受体蛋白质的三维结构图,该蛋白位于人体细胞的表面,并在调节免疫系统下属的补体系统中发挥着关键作用。

Immunity:Foxp3驱动的表观遗传修饰失控的危害

调节性T细胞(Treg)在限制自身免疫和慢性炎症中发挥着重要作用, 而调节性T细胞的生成由转录因子Foxp3调控。 5月10日,国际著名期刊Immunity 在线发表了圣犹大儿童研究医院等机构的一篇题为Loss of Epigenetic Modification Driven by the Foxp3 Transcription Factor Leads to Regulatory T Cel

JBC: NK细胞的激活需要络氨酸激酶Btk

Bruton酪氨酸激酶不仅对B细胞的发育及分化至关重要,也参与调节了Toll样受体(TLR)引起的巨噬细胞的先天性免疫反应。然而,Btk是否参与调节了NK细胞的先天性免疫功能目前还不明确。近日,来自第二军医大的研究人员阐明了该机制。 他们发现,在老鼠NK细胞的成熟及激活期间,Btk的表达表现上调。应答TLR3配体时,老鼠Btk-/- NK细胞的免疫反应下降,同时IFN-γ、穿孔素及颗粒酶B的表达